Recombinant Human VEGF-C / Flt4-L Protein, His Tag (MALS verified), 50µg

Background
Vascular endothelial growth factor C is also known as VEGFC, Flt4-L and VRP, it contains the C-terminal propeptide which has an unusual structure with tandemly repeated cysteine-rich motifs. Upon biosynthesis, VEGFC is secreted as a non-covalent momodimer in an anti-parellel fashion. VEGFC is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family, is active in angiogenesis, lymphangiogenesis and endothelial cell growth and survival, and can also affect the permeability of blood vessels. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-3 receptors. Only the fully processed form can bind and activate VEGFR-2 receptors. The structure and function of this protein is similar to those of vascular endothelial growth factor D (VEGF-D). VEGFC may function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Overexpression of VEGF-C causes lymphatics to enlarge possibly facilitates metastasis.

Source
Recombinant Human VEGF-C /FLT4L Protein (rhVEGF-C), His Tag (VEC-H4225) is expressed from human 293 cells (HEK293). It contains AA Thr 103 - Arg 227 (Accession # AAH35212.1).
Predicted N-terminus: Thr 103

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 14.9 kDa. The protein migrates as 19-25 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "VEGF-C prophylaxis favors lymphatic drainage and modulates neuroinflammation in a stroke model"
Boisserand, Geraldo, Bouchart et al
J Exp Med (2024) 221 (4)
(2) "Retraction: Expression of vascular endothelial growth factor C in renal cell carcinoma and its correlation with pathological parameters and prognosis"
Shi, Lv, Li et al
Transl Androl Urol (2024) 13 (1), 192
(3) "Blocking cerebral lymphatic system reduces central and peripheral inflammatory response in ischemic stroke"
Yang, Li, Wang et al
Brain Res (2024) 1831, 148825
Showing 1-3 of 3694 papers.